IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)

Oncotarget

Volumn 8, Issue 2, 2017, Pages 2731-2744

  Wege, Anja K ^a   Weber, Florian ^a   Kroemer, Alexander ^b   Ortmann, Olaf ^a   Nimmerjahn, Falk ^c   Brockhoff, Gero ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Breast cancer; Humanized tumor mice (HTM); IL 15; Immunomodulation; Trastuzumab

Indexed keywords

CD16 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; FC GAMMA RECEPTOR IIIA; HERMES ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 15; TRASTUZUMAB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; HYALURONIC ACID BINDING PROTEIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BINDING AFFINITY; BONE MARROW METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER MORTALITY; CANCER SURVIVAL; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; OVERALL SURVIVAL; PROTEIN BINDING; PROTEIN POLYMORPHISM; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENETIC POLYMORPHISM; GENETICS; IMMUNOMODULATION; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENOTYPE; HUMANS; HYALURONAN RECEPTORS; IMMUNOMODULATION; INTERLEUKIN-15; MICE; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, IGG; TRASTUZUMAB; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85009760467     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13159     Document Type: Article

References (46)

1. Pohlmann PR, Mayer IA and Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res. 2009; 15:7479-7491
2. Clynes RA, Towers TL, Presta LG and Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6:443-446
3. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, Kauraniemi P, Kapanen A, Tanner M and Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007; 6:2065-2072
4. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B and Da Prada G et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004; 10:5650-5655
5. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin J-F and Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94:259-267
6. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A and Fagnoni FF. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007; 67:11991-11999
7. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L and Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008; 6:25
8. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D and Miller JS. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res. 2003; 9:2440-2446
9. Tagliabue E, Campiglio M, Pupa SM, Menard S and Balsari A. Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev. 2012; 38:212-217
10. Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E and Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 2013; 11:307
11. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S and Denkert C et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25:1544-1550
12. Bianchini G and Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. The Lancet Oncology. 2014; 15:e58-e68
13. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL and Cook GP. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One. 2011; 6:e22842
14. Watanabe MAE, Oda JMM, Amarante MK and Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010; 29:569-579
15. Li H, Han Y, Guo Q, Zhang M and Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009; 182:240-249
16. Benson DM, JR, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P and Devine SM et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116:2286-2294
17. Ryan AE, Shanahan F, O'Connell J and Houston AM. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 2005; 65:9817-9823
18. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K and Suzuki M. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012; 40:929-934
19. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR and Graham CH. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011; 71:7433-7441
20. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K and Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994; 180:1395-1403
21. Kroemer G, Senovilla L, Galluzzi L, Andre F and Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015; 21:1128-1138
22. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H and Di Santo JP. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009; 206:25-34
23. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel DN, Ortmann O, Kroemer A and Brockhoff G. Humanized tumor micea new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer. 2011; 129:2194-2206
24. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 2015; 33:74-82
25. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC and Riddell SR. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009; 114:2417-2426
26. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR and van Lier RA. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997; 186:1407-1418
27. Vossen MTM, Matmati M, Hertoghs KML, Baars PA, Gent M-R, Leclercq G, Hamann J, Kuijpers TW and van Lier, Rene A W. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol. 2008; 180:3739-3745
28. Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O and Brockhoff G. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Cytometry A. 2011; 79:684-693
29. Stoklasek TA, Schluns KS and Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177:6072-6080
30. Dubois S, Patel HJ, Zhang M, Waldmann TA and Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol. 2008; 180:2099-2106
31. Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A, Sherwood ER. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ. J Immunol. 2015; 195:2353-64
32. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne, A E and Haas M de. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997; 90:1109-1114
33. Weng W-K and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003; 21:3940-3947
34. Dornan D, Spleiss O, Yeh R-F, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J and Catalano J et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010; 116:4212-4222
35. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA and Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001; 276:6591-6604
36. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM and Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26:1789-1796
37. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX and Robert NJ et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012; 18:3478-3486
38. Roca L, Dieras V, Roche H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon J-L, Spielmann M, Penault-Llorca F, Martin A-L, Mesleard C and Lemonnier J et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat. 2013; 139:789-800
39. Kim J-W, Kim JH, Im S-A, Kim YJ, Han H-S, Kim J-S, Han S-W, Jeon YK, Oh D-Y, Han W, Kim T-Y, Park IA and Noh D-Y et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology. 2012; 83:218-227
40. Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F and D'Alonzo A et al. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcgammaRIIIA/FcgammaRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015; 13:324
41. Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, Strohl WR, Zou Q, Zhang N and An Z. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages. J Immunol. 2015; 194:4379-4386
42. Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C and Esteva FJ. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015; 151:501-513
43. Palyi-Krekk Z, Barok M, Isola J, Tammi M, Szollosi J and Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer. 2007; 43:2423-2433
44. Jaggupilli A and Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012; 2012:708036
45. Fillmore C and Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res. 2007; 9:303
46. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE and Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997; 100:1059-1070